These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34964405)

  • 1.
    Zhang J; Huang J; He X; Li N; Miao Y; Li B; Shao X; Wang N
    Gynecol Endocrinol; 2022 Feb; 38(2):170-175. PubMed ID: 34964405
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Zhang J; Huang J; He X; Li N; Miao Y; Li B; Shao X; Wang N
    Gynecol Endocrinol; 2022 Apr; 38(4):318-323. PubMed ID: 35285758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome.
    Di Pietro M; Pascuali N; Scotti L; Irusta G; Bas D; May M; Tesone M; Abramovich D; Parborell F
    Mol Hum Reprod; 2017 Jun; 23(6):417-427. PubMed ID: 28379469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
    Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F
    Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Montelukast is effective in preventing of ovarian hyperstimulation syndrome; an experimental study.
    Eskicioğlu F; Turan GA; Sivrikoz ON; Cengiz H; Zafer A; Akan Z; Sahin N; Yilmaz O; Yeşil H; Vatansever S
    Ginekol Pol; 2015 Aug; 86(8):566-73. PubMed ID: 26492704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxytocin and cabergoline alleviate ovarian hyperstimulation syndrome (OHSS) by suppressing vascular endothelial growth factor (VEGF) in an experimental model.
    Hortu I; Karadadas E; Ozceltik G; Tavmergen E; Tavmergen Goker EN; Yigitturk G; Erbas O
    Arch Gynecol Obstet; 2021 Apr; 303(4):1099-1108. PubMed ID: 33140116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
    Kosmas IP; Kitsou C; Lazaros L; Markoula S; Peschos D; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos A; Galani V; Georgiou I
    Gynecol Endocrinol; 2015; 31(9):702-7. PubMed ID: 26172931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats.
    Ishikawa K; Ohba T; Tanaka N; Iqbal M; Okamura Y; Okamura H
    Endocr J; 2003 Oct; 50(5):515-25. PubMed ID: 14614207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model.
    Quintana R; Kopcow L; Marconi G; Young E; Yovanovich C; Paz DA
    Fertil Steril; 2008 Oct; 90(4 Suppl):1511-6. PubMed ID: 18166186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability.
    Gómez R; Simón C; Remohí J; Pellicer A
    Biol Reprod; 2003 Jun; 68(6):2164-71. PubMed ID: 12606463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome.
    Jellad S; Haj Hassine A; Basly M; Mrabet A; Chibani M; Rachdi R
    J Gynecol Obstet Hum Reprod; 2017 Jan; 46(1):87-91. PubMed ID: 28403961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aflibercept suppresses ovarian hyperstimulation syndrome: an experimental study in rats.
    Ateş Ç; Dilbaz B; Ergani SY; Atabay F
    Rev Assoc Med Bras (1992); 2023; 69(11):e20230789. PubMed ID: 37909622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the impact of short- and long-term supplementation of either cabergoline or clarithromycin on resolving rat ovarian hyperstimulation syndrome (OHSS) model?
    Atilgan R; Pala Ş; Yavuzkır Ş; Başpınar M; Yılmaz M; Ilhan N
    J Obstet Gynaecol; 2019 Jul; 39(5):687-694. PubMed ID: 30892121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of resveratrol on ovarian hyperstimulation syndrome in a rat model.
    Ozgur S; Oktem M; Altinkaya SO; Oktem EO; Cenksoy C; Erdem O; Elbeg S; Helvaci A; Erdem A; Erdem M
    Taiwan J Obstet Gynecol; 2018 Jun; 57(3):383-388. PubMed ID: 29880170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys.
    Bishop CV; Lee DM; Slayden OD; Li X
    J Ovarian Res; 2017 Jul; 10(1):41. PubMed ID: 28683759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
    van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
    Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
    Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.